NCT04354909View on ClinicalTrials.gov

Soluble CD95 Ligand Role in the Pathophysiology of Non-infectious Active Uveitis

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

March 10, 2023

Study Completion Date

March 10, 2023

Conditions
Non-Infectious Active Uveitis
Interventions
OTHER

s-CD95-L

levels of s-CD95-L (ELISA test)

Trial Locations (1)

Unknown

CHU Bordeaux, Bordeaux

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER

NCT04354909 - Soluble CD95 Ligand Role in the Pathophysiology of Non-infectious Active Uveitis | Biotech Hunter | Biotech Hunter